A Southwest Oncology Group study
A Southwest Oncology Group study
复制标题
DOI：
--
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
T. Jenkins;C. Tangen;J. Macdonald;G. Weiss;R. Chapman;A. Hantel
中科院分区：
文献类型：
--
作者：
T. Jenkins;C. Tangen;J. Macdonald;G. Weiss;R. Chapman;A. Hantel
摘要 西南肿瘤学组在晚期胃癌患者中进行了 VM-26（替尼泊苷）试验。每21天每天给予VM-26 60 mg/m 2 静脉输注30-45分钟，持续5天。对 21 名具有可测量疾病且 SWOG 表现状态为 0-2 的合格患者进行了反应和毒性分析。 21 名符合条件的患者中有 2 名出现部分缓解（9.5%）。中位生存期为 3.8 个月。 13/21 (62%) 的患者观察到严重或危及生命的毒性。其中包括两例与中性粒细胞减少性脓毒症相关的药物相关死亡，以及另外七例 4 级粒细胞减少症 (< 500/mmJ) 患者。肝功能障碍和低血压较少见，且不受剂量限制。尽管所观察到的适度活性与 VP-16（依托泊苷）作为单一药物的活性相当，但本试验中观察到的血液学毒性可能会妨碍 VM-26（替尼泊苷）在晚期胃癌中的进一步试验。
Summary The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m 2 IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5 %). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mmJ). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.